MedTrace Logo

Efficacy and Safety of SR-T100 Gel in Common Warts (CW) Patients

NCT01796795 · Status: SUSPENDED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 102

Last updated 2023-09-14

No results posted yet for this study

Summary

This phase II study is to evaluate the efficacy of SR-T100 gel in complete clearance of target warts at different concentrations (1.0% and 2.3% of SM in Solanum undatum plant extract) in patients with CW.

Conditions

  • Common Wart

Interventions

DRUG

Vehicle gel

Topical application on the target lesion(s)once daily with occlusive dressing; a maximum of 3 times of administration of gel without exceeding 0.2 g per administration.

DRUG

SR-T100 gel with 1.0% of SM

Topical application on the target lesion(s)once daily with occlusive dressing; a maximum of 3 times of administration of gel without exceeding 0.2 g per administration.

DRUG

SR-T100 gel with 2.3% of SM

Topical application on the target lesion(s)once daily with occlusive dressing; a maximum of 3 times of administration of gel without exceeding 0.2 g per administration.

Sponsors & Collaborators

  • G&E Herbal Biotechnology Co., LTD

    lead INDUSTRY

Principal Investigators

  • Kou-Wha Kuo, Ph.D · G&E Herbal Biotechnology Co., LTD

  • Hamm-Ming Sheu, MD · National Cheng-Kung University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2030-09-30
Primary Completion
2033-04-30
Completion
2033-08-31
FDA Drug
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01796795 on ClinicalTrials.gov